Accepted Manuscript

Title: Disease-modifying drug therapy in CF

Authors: Katharine Harman, Rebecca Dobra, Jane C. Davies

PII: \$1526-0542(17)30031-3

DOI: http://dx.doi.org/doi:10.1016/j.prrv.2017.03.008

Reference: YPRRV 1206

To appear in: *YPRRV*

Please cite this article as: Harman Katharine, Dobra Rebecca, Davies Jane C.Disease-modifying drug therapy in CF. Paediatric Respiratory Reviews http://dx.doi.org/10.1016/j.prrv.2017.03.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Disease-modifying drug therapy in CF

Katharine Harman, Rebecca Dobra, Jane C Davies
Imperial College London & Royal Brompton & Harefield NHS Trust, London, UK

Corresponding author:

Jane C Davies

Professor of Paediatric Respirology & Experimental Medicine

Imperial College London

j.c.davies@imperial.ac.uk

020 7351 8398

Summary

Whilst substantial progress has been made in the treatment of cystic fibrosis, the disease still carries a significant burden in terms of symptoms, requirement for treatment and early mortality. The last decade has witnessed a new era in the development of small molecule drugs targeting the CFTR protein, which for the first time may provide a truly disease-modifying approach to treatment. This article reviews progress and highlights some of the current and future challenges in CFTR modulator therapies.

Key words: potentiator, corrector, read-through, CFTR

Download English Version:

https://daneshyari.com/en/article/8813014

Download Persian Version:

https://daneshyari.com/article/8813014

<u>Daneshyari.com</u>